keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy neuropathy

keyword
https://www.readbyqxmd.com/read/28097895/chemotherapy-induced-peripheral-neuropathy-limitations-in-current-prophylactic-strategies-and-directions-for-future-research
#1
Marco Cascella
No abstract text is available yet for this article.
January 18, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28079002/neurotoxicity-associated-with-platinum-based-anti-cancer-agents-what-are-the-implications-of-copper-transporters
#2
Vanesa Stojanovska, Rachel McQuade, Emma Rybalka, Kulmira Nurgali
Platinum-based anti-cancer agents, which include cisplatin, carboplatin and oxaliplatin, are an important class of drugs used in clinical setting to treat a variety of cancers. The cytotoxic efficacy of these drugs is mediated by the formation of interstrand and intrastrand crosslinks, or platinum adducts on nuclear DNA. There is also evidence demonstrating that mitochondrial DNA is susceptible to platinum-adduct damage in dorsal root ganglia neurons. Although all platinum-based agents form similar DNA adducts, they are quite different in terms of activation, systemic toxicity and tolerance...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28069154/the-assessment-and-management-of-chemotherapy-related-toxicities-in-patients-with-breast-cancer-colorectal-cancer-and-hodgkin-s-and-non-hodgkin-s-lymphomas-a-scoping-review
#3
Patricia Fox, Andrew Darley, Eileen Furlong, Christine Miaskowski, Elisabeth Patiraki, Jo Armes, Emma Ream, Constantina Papadopoulou, Lisa McCann, Nora Kearney, Roma Maguire
PURPOSE: The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice...
February 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28068938/acupuncture-combined-with-methylcobalamin-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-multiple-myeloma
#4
Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. METHODS: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture)...
January 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28063866/chemotherapy-induced-neuropathy-in-cancer-survivors
#5
Christine Miaskowski, Judy Mastick, Steven M Paul, Kimberly Topp, Betty Smoot, Gary Abrams, Lee-May Chen, Kord M Kober, Yvette P Conley, Margaret Chesney, Kay Bolla, Grace Mausisa, Melissa Mazor, Melisa Wong, Mark Schumacher, Jon D Levine
CONTEXT: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. OBJECTIVES: To evaluate between group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n=426) and did not (n=197) develop CIN...
January 4, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28061451/nanoparticle-albumin-bound-paclitaxel-as-neoadjuvant-chemotherapy-of-breast-cancer-a-systematic-review-and-meta-analysis
#6
REVIEW
Yu Zong, Jiayi Wu, Kunwei Shen
BACKGROUND: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain. METHODS: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28050144/effect-of-chemotherapy-on-health-related-quality-of-life-among-early-stage-ovarian-cancer-survivors-a-study-from-the-population-based-profiles-registry
#7
C S Bhugwandass, J M A Pijnenborg, B Pijlman, N P M Ezendam
BACKGROUND: There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment. METHODS: All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28041630/the-analgesic-effect-of-orexin-a-in-a-murine-model-of-chemotherapy-induced-neuropathic-pain
#8
Satoshi Toyama, Naohito Shimoyama, Megumi Shimoyama
Orexins are neuropeptides that are localized to neurons in the lateral and dorsal hypothalamus but its receptors are distributed to many different regions of the central nervous system. Orexins are implicated in a variety of physiological functions including sleep regulation, energy homeostats, and stress reactions. Furthermore, orexins administered exogenously have been shown to have analgesic effects in animal models. A type of intractable pain in patients is pain due to chemotherapy-induced peripheral neuropathy (CIPN)...
December 24, 2016: Neuropeptides
https://www.readbyqxmd.com/read/28033158/a-review-of-adult-and-pediatric-neuropathic-pain-assessment-tools
#9
Kyle Joseph Morgan, Doralina L Anghelescu
An early and thorough assessment of pain is essential to its proper diagnosis and treatment. This assessment is especially important when NP is suspected, given the different treatment modalities available and the serious impact of NP on patients' quality of life. This article summarizes the various screening and assessment tools available to clinicians for evaluating NP. Despite the availability of the 15 tools discussed, a deficiency remains, particularly in the pediatric realm. To date, there is no well-validated NP assessment tool for children younger than 5 years, no pediatric NP screening tool that has been validated outside the domain of chemotherapy-induced peripheral neuropathy, and no consistent recommendation regarding the optimal tool to use with pediatric patients who have chronic pain...
December 28, 2016: Clinical Journal of Pain
https://www.readbyqxmd.com/read/28032218/symptom-clusters-during-palliative-chemotherapy-and-their-influence-on-functioning-and-quality-of-life
#10
Sun Young Rha, Jiyeon Lee
INTRODUCTION: Symptom management in patients undergoing palliative chemotherapy is challenging, as patients may suffer from cancer symptoms as well as symptoms related to chemotherapy. Symptom clusters are interrelated symptoms occurring simultaneously that exert a negative impact on survival. Identification of symptom clusters and effective symptom management for patients receiving palliative chemotherapy is crucial. OBJECTIVES: The purpose of this study was to identify symptom clusters among cancer patients undergoing palliative chemotherapy and examine the relationship between symptom clusters and functioning and quality of life (QOL) in these patients...
December 28, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28029447/a-phase-ii-evaluation-of-ixabepilone-in-the-treatment-of-recurrent-persistent-carcinosarcoma-of-the-uterus-an-nrg-oncology-gynecologic-oncology-group-study
#11
Carolyn K McCourt, Wei Deng, Don S Dizon, Heather A Lankes, Michael J Birrer, Michele M Lomme, Matthew A Powell, James E Kendrick, Joel N Saltzman, David Warshal, Meaghan E Tenney, David M Kushner, Carol Aghajanian
BACKGROUND: The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Exploratory translational objectives included characterization of class III beta tubulin expression and its association with response, PFS, and OS. METHODS: Patients had measurable disease; up to two prior chemotherapeutic regimens were allowed, but must have included a taxane...
October 28, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/28028256/-treatment-continuation-and-safety-of-eribulin-for-the-treatment-of-metastatic-breast-cancer
#12
Shino Adachi, Eiseki Usami, Kazutomo Okada, Mina Iwai, Hiroki Asano, Daisuke Ito, Keitaro Kamei, Tomoaki Yoshimura
The purpose of treatment for patients with metastatic breast cancer is to maintain the patient's quality of life(QOL)with continued treatment for as long as possible.Eribulin was approved in April 2011 for the treatment of metastatic breast cancer, further increasing the selection of therapies available for the management of this disease.The current study presents a retrospective review of 31 patients who received eribulin in our hospital, and analyzes the factors related to the continuation and safety of its use...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28012171/mir-15b-mediates-oxaliplatin-induced-chronic-neuropathic-pain-through-bace1-downregulation
#13
Naomi Ito, Atsushi Sakai, Noriko Miyake, Motoyo Maruyama, Hirotoshi Iwasaki, Koichi Miyake, Takashi Okada, Atsuhiro Sakamoto, Hidenori Suzuki
BACKGROUND AND PURPOSE: Although oxaliplatin is an effective anti-cancer platinum compound, it can cause painful chronic neuropathy, and its molecular mechanisms remain poorly understood. MicroRNAs are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Although microRNAs have been increasingly recognised as important modulators in a variety of pain conditions, their involvement in chemotherapy-induced neuropathic pain is unknown. EXPERIMENTAL APPROACH: Oxaliplatin-induced chronic neuropathic pain was induced in rats by intraperitoneal oxaliplatin injections (2 mg kg(-1) ) for 5 consecutive days...
December 23, 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28004441/referred-symptom-from-myofascial-pain-syndrome-one-of-the-most-important-causes-of-sensory-disturbance-in-breast-cancer-patients-using-taxanes
#14
E J Ko, J Y Jeon, W Kim, J Y Hong, Y G Yi
The aim of this retrospective study was to evaluate common causes of upper extremity sensory disturbance in breast cancer patients. Breast cancer patients who received surgery and taxane chemotherapy (CTx) with upper extremity sensory disturbance that began after CTx were included. With comprehensive clinical history, physical examination and electrodiagnostic results, diagnosis for each patient was made. Fifty-two patients were included: 23 (44.2%) were diagnosed with chemotherapy-induced peripheral neuropathy (CIPN), 7 (13...
December 22, 2016: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28002115/pilot-testing-a-web-based-system-for-the-assessment-and-management-of-chemotherapy-induced-peripheral-neuropathy
#15
Robert Knoerl, William N Dudley, Gloria Smith, Celia Bridges, Grace Kanzawa-Lee, Ellen M Lavoie Smith
Because numerous barriers hinder the assessment and management of chemotherapy-induced peripheral neuropathy in clinical practice, the Carevive Care Planning System, a novel Web-based platform, was developed to address these barriers. It provides patients an opportunity to report their symptoms before their clinic visit and generates customizable care plans composed of evidence-based management strategies. The purpose of this study was to evaluate patient and provider perspectives of feasibility, usability, acceptability, and satisfaction with the Carevive platform...
December 20, 2016: Computers, Informatics, Nursing: CIN
https://www.readbyqxmd.com/read/27994483/clinical-effects-of-prior-trastuzumab-on-combination-eribulin-mesylate-plus-trastuzumab-as-first-line-treatment-for-human-epidermal-growth-factor-receptor-2-positive-locally-recurrent-or-metastatic-breast-cancer-results-from-a-phase-ii-single-arm-multicenter
#16
Shannon Puhalla, Sharon Wilks, Adam M Brufsky, Joyce O'Shaughnessy, Lee S Schwartzberg, Erhan Berrak, James Song, Linda Vahdat
Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for the treatment of patients with metastatic breast cancer who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a Phase II trial for the first-line combination of eribulin plus trastuzumab in human epidermal growth factor receptor 2 positive patients showed a 71% objective response rate and tolerability consistent with the known profile of these agents...
2016: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/27992556/bevacizumab-exacerbates-paclitaxel-induced-neuropathy-a-retrospective-cohort-study
#17
Ayumu Matsuoka, Osamu Maeda, Takefumi Mizutani, Yasuyuki Nakano, Nobuyuki Tsunoda, Toyone Kikumori, Hidemi Goto, Yuichi Ando
BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that VEGF receptor inhibitors can interfere with the neuroprotective effects of endogenous VEGF, potentially triggering the exacerbation of PTX-induced neuropathy. In clinical trials, exacerbation of neuropathy in patients who received PTX combined with BEV (PTX+BEV) has generally been explained by increased exposure to PTX owing to the extended duration of chemotherapy...
2016: PloS One
https://www.readbyqxmd.com/read/27984530/clinical-assessment-of-new-antineuropathic-strategies-for-chemotherapy-induced-peripheral-neuropathy-pain-should-not-be-the-principal-endpoint
#18
Nicolas Kerckhove, Bruno Pereira, Denis Pezet, David Balayssac
No abstract text is available yet for this article.
January 2017: Pain
https://www.readbyqxmd.com/read/27981569/genetic-advances-uncover-mechanisms-of-chemotherapy-induced-peripheral-neuropathy
#19
Katherina C Chua, Deanna L Kroetz
No abstract text is available yet for this article.
December 16, 2016: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27980107/niclosamide-inhibits-oxaliplatin-neurotoxicity-while-improving-colorectal-cancer-therapeutic-response
#20
Olivier Cerles, Evelyne Benoit, Christiane Chéreau, Sandrine Chouzenoux, Florence Morin, Marie-Anne Guillaumot, Romain Coriat, Niloufar Kavian, Thomas Loussier, Pietro Santulli, Louis Marcellin, Nathaniel E B Saidu, Bernard Weill, Frederic Batteux, Carole Nicco
Neuropathic pain is a limiting-factor of platinum-based chemotherapies. We sought to investigate the neuroprotective potential of niclosamide in peripheral neuropathies induced by oxaliplatin. Normal neuron-like and cancer cells were treated in vitro with oxaliplatin associated or not with an inhibitor of STAT3 and NF-кB, niclosamide. Cell production of reactive oxygen species and viability were measured by 2',7'-dichlorodihydrofluorescein diacetate and crystal violet. Peripheral neuropathies were induced in mice by oxaliplatin with or without niclosamide...
December 15, 2016: Molecular Cancer Therapeutics
keyword
keyword
70500
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"